Principal Investigator
Gilberto Lopes
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20231000
Clinical Trial Summary
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3 targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas.
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Thoracic Oncology
Contact Information
Phone Number
305-243-2647